#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Is there dependence between the level of adipocyte fatty acid-binding protein and calcium score in asymptomatic relatives of patients with cardiovascular diseases?


Authors: E. Sovová 1;  J. Vrbková 2;  D. Stejskal 3;  M. Kaletová 1;  M. Kamínek 4;  I. Metelková 4;  M. Sova 5;  I. Benušová 1;  P. Doupalová 1
Authors‘ workplace: I. interní klinika - kardiologická Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Miloš Táborský, CSc., MBA 1;  Katedra matematické analýzy a aplikací matematiky Přírodovědecké fakulty UP Olomouc, vedoucí prof. RNDr. Jan Andres, DrSc. 2;  Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc. 3;  Klinika nukleární medicíny Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Pavel Koranda, Ph. D. 4;  Klinika plicních nemocí a tuberkulózy Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vítězslav Kolek, DrSc. 5
Published in: Vnitř Lék 2013; 59(1): 31-36
Category: Original Contributions

Overview

The objective of our study was to determine a correlation between the level of adipocyte fatty acid-binding protein (A-FABP) (as a possible link between metabolic syndrome and atherosclerosis), the calcium score (CS) and laboratory parameters, including insulin resistance indices in asymptomatic first degree relatives of patients with cardiovascular diseases.

Set and methodology:
Examination was conducted in 82 persons (53 male) with the average age of 52.79 ± 9.6. The examinations consisted of anthropometric and physical tests (determination of body weight, height, body mass index – BMI and casual blood pressure measurement), laboratory analysis (uric acid, creatinine, lipid panel, insulin, glucose, C-reactive protein, fibrinogen, glycated hemoglobin, adipocyte fatty acid-binding protein – A-FABP) and determination of insulin resistance indices HOMA and QUICKI. Total calcium score (CS) was determined by the Agatston method without the need to administer a contrast agent.

Results:
The value of the A-FABP level does not show a statistically significant dependence on the categorised CS or on non-categorised CS values. There is a statistically significant positive dependence of the level of A-FABP on the HOMA index (p = 0.00688) and a statistically significant negative dependence on the QUICKI index (p = 0.0068). The A-FABP level is statistically significantly higher in women (p = 0.048), in elder persons (p = 0.043), and in persons with higher BMI values (p = 0.029). Among continuous variables, statistically significant is the difference in the A-FABP level in relation to age (p = 0.002), creatinine (p = 0.026), insulin (p = 0.005), and BMI (p = 0.031).

Conclusion:
Our study confirmed the correlation of the A-FABP level with insulin resistance indices, BMI, age, gender, and insulin and creatinine levels in a group of asymptomatic first degree relatives of patients with cardiovascular diseases. A-FABP could potentially be a marker when determining the risk of CVD; however, this conclusion requires additional clinical trials.

Key words:
adipocyte fatty acid-binding protein – calcium score – cardiovascular diseases – insulin resistance


Sources

1. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Dostupné na http://www.escardio.org/guidelines-surveys/ 14.7.2012.

2. Shaw LJ, Raggi P, Callister TQ et al. Prognostic value of coronary artery calcium screening in asymptomatic smokers and non smokers. Eur Heart J 2006; 27: 968–975.

3. Hoff JA, Daviglus ML, Chomka EV et al. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30,908 healthy individuals. Ann Epidemiol 2003; 13: 163–169.

4. Taylor AJ, Bindeman J, Feuerstein I et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors. J Am Coll Cardiol 2005; 46: 807–814.

5. Writing Committee Members; ACC/AHA Task Force Members. 2010 ACCF/AHA Guidelines for assessment of cardiovascular risk in asymptomatic adults: executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis imaging and preventive, Society of Cardiovascular Angiography and Interventions, Society od Cardiovascular Computed Tomography, and Society of Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010; 56: 2182–2199.

6. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008; 28: 73–95.

7. Tuncman G, Erbay E, Hom X et al. A functional genetic variant at the fatty acid binding protein, aP2, locus reduces the risk for hypertriglyceridemia, type 2 diabetes and cardiovascular disease. Proc Natl Acad Sci USA 2005; 103: 6970–6975.

8. Tso AWK, Xu A, Sham PC et al. Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 dia­betes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30: 2667–2672.

9. Erbay E, Cao H, Hotamisligil GS. Adipocyte//macrophage fatty acid binding proteins in metabolic syndrome. Curr Atheroscler Rep 2007; 9: 222–229.

10. Hsu BG, Chen YC, Lee RP et al. Fasting serum level of fatty-acid- binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 2010; 74: 327–331.

11. Makowski L, Boord JB, Maeda K et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699–705.

12. Miyoshi T, Onoue G, Hirohata A et al. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010; 211: 164–169.

13. Rhee EJ, Lee WY, Park CY et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009; 160: 165–172.

14. Krusinova E, Pelikanova T. Fatty acid binding proteins in adipose tissue: A promising link between metabolic syndrome and atherosclerosis? Diabetes Research and Clinical Practice 2008; 82: (Suppl. 2): 127–134.

15. Makowski L, Brittingham KC, Reynolds JM et al. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome preliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005; 280: 12888–12895.

16. Peeters W, de Kleijn DPV, Vink A et al. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 2011; 32: 1758–1768.

17. Doi M, Miyoshi T, Hirohata S et al. Asso­ciation of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol 2011; 10: 44.

18. Bagheri R, Quasim AN, Mehta NN et al. Relation of plasma fatty acid bindings proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type 2 diabetes mellitus. Am J Cardiol 2010; 106: 1118–1123.

19. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402–2410.

20. Agatston AS, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832.

21. Metelková I, Kamínek M, Sovová E et al. Stratifikace rizika pomocí zátěžového SPECT zobrazení myokardu v kombinaci se stanovením koronárního kalciového skóre u rizikových pacientů s diabetem a/nebo ledvinným selháním. Vnitř Lék 2010; 56: 1122–1129.

22. Horakova D, Stejskal D, Pastucha D et al. Potential markers of insuline resistance in healthy vs obese and overweight subjects. Biomed Pap Med Fac Univ Palacky Olomouc Czech. Repub 2010; 154: 245–250.

23. Horáková D, Pastucha D, Stejskal D et al. Adipocyte fatty acid binding protein and C reactive protein levels as indicators of insulin resistence development. Biomed Pap Med Fac Univ Palacky Olomouc Czech. Repub 2011; 155: 355–360.

24. Engl J, Ciardi C, Tatarczyk T et al. A-FABP – a biomarker associated with the metabolic syndrome and/or an indicator of weight change? Obezity 2008; 16: 1838–1842.

25. Stejskal D, Karpisek M, Bronsky J. Serum adipocyte-fatty acid binding protein discriminates patients with permanent and temporary body weight loss. J Clin Lab Analysis 2008; 22: 380–382.

26. Cabré A, Lázaro I, Girona J et al. Plasma fatty acid binding protein 4 increases with renal dysfunction in type 2 diabetic patients without mikroalbuminuria. Clinical Chemistry 2008; 54: 181–187.

27. Iwamoto M, Miyoshi T, Masayuki H et al. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovascular Diabetology 2012; 11: 26–34.

28. Karpisek M, Stejskal D, Kotolova H et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in pa­tients with hyperlipidemia. Eur J Clin Invest 2007; 37: 637–642.

29. Cabré A, Babio N, Bullo M et al. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. Atherosclerosis 2012; 222: 229–234.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#